Skip to main content
. 2015 Jan 13;2015(1):CD010767. doi: 10.1002/14651858.CD010767.pub2

1. Summary of trial characteristics.

Trial Bojang 2010 GMB Cox 2013 GMB Desai 2003 KEN Phiri 2012 MWI Verhoef 2002 KEN Tomashek 2001 TNZ
Sample size (n randomized) 1200 96 554 1431 328 238
Country The Gambia (Banjul) The Gambia Kenya (Western Kenya) Malawi (southern Malawi) Kenya (Eastern province) Tanzania (Kigoma region)
Endemicity low* low* high* high* low* moderate/high (50% parasitaemia)**
Age 3 months to 9 years 12 to 72 months 2 to 36 months 4 to 59 months 2 to 36 months 6 to 59 months
Anaemia Hb < 7 g/dL Hb 69 to 110 g/L Hb 7.0 to 10.9 g/dL All children treated for severe malarial anaemia with transfusion and completed the course of intravenous quinine with subsequent Hb > 5g/dL Hb 60 to 110 g/L Hb 5.0 to 8.0 g/dL
Malaria Not criteria for inclusion. Children with malaria were treated Uncomplicated malaria No malaria (aparasitaemic) or parasite counts < 20,000 parasites/mm3 No clinical malaria Not described as part of eligibility
Recruitment Hospital or OPD admission Active and passive case finding of children in community Community: resident children screened Hospital admissions Community: randomly selected Health care worker diagnosed children with clinical anaemia and referred them to the trial
Trial intervention

  1. IPT (SP)

  2. Placebo

  1. IPT (CQ)

  2. Placebo

  1. IPT (SP) + iron

  2. IPT (SP) + iron placebo

  3. Iron + IPT placebo

  4. Iron placebo + IPT placebo

  1. IPT(post discharge): AL

  2. Placebo

  1. IPT (SP) + iron

  2. IPT (SP) + iron placebo

  3. Iron + IPT placebo

  4. Iron placebo + IPT placebo

  1. Vitamin placebo 3X per week

  2. Vitamin placebo + IPT (SP)

  3. VAC + IPT (SP)
Iron and other supplementation during trial period (all participants) Yes: oral iron for 28 days No No ‐ part of trial intervention Not reported No – part of trial intervention Yes: Iron and folic acid for 12 weeks
Baseline treatment for all participants Some were treated with quinine and SP or CQ and SP. Not all children Either CQ and SP or AL Single dose of SP 3 day course of AL
 in hospital (6 doses) None Single dose of SP; mebendazole for participants > 12 months

*endemicity derived from the Malaria Atlas Project (Gething 2011).

**as reported in the trial (Tomashek 2001 TNZ).

Abbreviations:

Hb: Haemoglobin

OPD: Out patient department

IPT: Intermittent preventive treatment

SP:Sulfadoxine‐pyrimethamine

CQ: Chloroquine

AL: Arthemeter‐lumefantrine

VAC: Vitamin A and C